Status:
COMPLETED
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
Lead Sponsor:
Changi General Hospital
Conditions:
Major Depression
Generalized Anxiety Disorder
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, w...
Detailed Description
This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood p...
Eligibility Criteria
Inclusion
- Give informed consent
- Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder
- Aged 21 years old and above
- Able to comprehend and comply with protocol
- Not pregnant and if of child-bearing age, using adequate methods of contraception
Exclusion
- Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs
- Contraindications to escitalopram
- Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease
- History of non-response to escitalopram
- Meets IDF definition of metabolic syndrome
- Significant risk of suicide
- Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00711737
Start Date
September 1 2008
End Date
October 1 2010
Last Update
June 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changi General Hospital
Singapore, Singapore, 529889